Business
IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026
POTOMAC, MD / ACCESS Newswire / March 18, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced it will demonstrate its Agentic ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"POTOMAC, MD / ACCESS Newswire / March 18, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced it will demonstrate its Agentic Harmonization Assistant ("AHA"), an artificial intelligence platform designed to automate the integration and analysis of complex biomedical datasets, at the Alzheimer's & Parkinson's Diseases Conference (ADPD) 2026.","length":510,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"IGC Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":624,"height":369,"url":"https://media.zenfs.com/en/accesswire.ca/3011979a348f677090c0df904853b342"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8xFZnDCqJFbBvUhEVCsZfQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2ODtjZj13ZWJw/https://media.zenfs.com/en/accesswire.ca/3011979a348f677090c0df904853b342","width":624,"height":369}},"href":"https://app.accessnewswire.com/imagelibrary/c0b93cea-a03b-452b-a9e2-f6a696eb6c79/1148771/igcpharma-logo.jpg","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The demonstration will take place in collaboration with the Alzheimer's Disease Data Initiative (ADDI), a global data-sharing platform supported by Gates Ventures and leading research institutions focused on accelerating discoveries in neurodegenerative disease.","length":266,"tagName":"p"},{"type":"text","content":"AHA is an agent-based AI platform designed to harmonize fragmented datasets across multiple studies, including clinical trial data, imaging, and other biomedical information. Data harmonization remains one of the most time-consuming steps in Alzheimer's research, often requiring months of manual preparation before meaningful analysis can begin. By automating this process, AHA is designed to significantly reduce the time required to prepare large datasets for analysis.","length":476,"tagName":"p"},{"type":"text","content":""Artificial intelligence is becoming an increasingly important component of modern biomedical research," said Ram Mukunda, CEO of IGC Pharma. "Demonstrating AHA within the ADDI ecosystem at ADPD provides an opportunity to showcase how AI-driven data integration can accelerate insig...